HBV2023* ; Allweiss, L.* ; Cohen, C.* ; Dias, J.M.L.* ; Fumagalli, V.* ; Guo, H.* ; Harris, J.M.* ; Hu, J.* ; Iannacone, M.* ; Isogawa, M.* ; Jeng, W.J.* ; Kim, K.H.* ; Kramvis, A.* ; Li, W.* ; Lucifora, J.* ; Muramatsu, M.* ; Neuveut, C.* ; Ploss, A.* ; Pollicino, T.* ; Protzer, U. ; Tan, A.* ; Tanaka, Y.* ; Tu, T.* ; Tsukuda, S.* ; Thimme, R.* ; Urban, S.* ; Watashi, K.* ; Yuan, Z.* ; Yeh, S.H.* ; McKeating, J.A.* ; Revill, P.A.*
Highlights from the 2023 international meeting on the molecular biology of hepatitis B virus.
J. Gen. Virol. 105:001978 (2024)
Steer, B. ; Adler, B.* ; Adler, H.
Open reading frames M12/M13 jointly contribute to MHV-68 latency.
J. Gen. Virol. 104:8 (2023)
Olbrich, L.* ; Castelletti, N. ; Schälte, Y. ; Garí, M. ; Pütz, P. ; Bakuli, A.* ; Pritsch, M.* ; Kroidl, I.* ; Saathoff, E.* ; Guggenbüehl Noller, J.M.* ; Fingerle, V.* ; Le Gleut, R. ; Gilberg, L.* ; Brand, I.* ; Falk, P.* ; Markgraf, A.* ; Deák, F.* ; Riess, F.* ; Diefenbach, M.* ; Eser, T.* ; Weinauer, F.* ; Martin, S.* ; Quenzel, E.M.* ; Becker, M.* ; Durner, J.* ; Girl, P.* ; Müller, K.* ; Radon, K.* ; Fuchs, C. ; Wölfel, R.* ; Hasenauer, J. ; Hoelscher, M.* ; Wieser, A.*
Head-to-head evaluation of seven different seroassays including direct viral neutralisation in a representative cohort for SARS-CoV-2.
J. Gen. Virol. 102:001653 (2021)
Marschall, M.* ; Strojan, H.* ; Kiener, R.* ; Wangen, C.* ; Sonntag, E.* ; Müller, R.* ; Zeitträger, I.* ; Wagner, S.* ; Stamminger, T.* ; Milbradt, J.* ; Behrends, U. ; Körber, N. ; Bauer, T. ; Schrödel, S.* ; Thirion, C.* ; Wagner, R.* ; Hutterer, C.*
Differential upregulation of host cell protein kinases by the replication of α-, β- and γ-Herpesviruses provides a signature o virus-specific signalling.
J. Gen. Virol. 101, 284-289 (2020)
D'Arienzo, V.* ; Magri, A.* ; Harris, J.M.* ; Wing, P.A.C.* ; Ko, C. ; Rubio, C.O.* ; Revill, P.A.* ; Protzer, U. ; Balfe, P.* ; McKeating, J.A.*
A PCR assay to quantify patterns of HBV transcription.
J. Gen. Virol. 102:001373 (2019)
de Sousa-Pereira, P. ; Abrantes, J.* ; Bauernfried, S.* ; Pierini, V.* ; Esteves, P.J.* ; Keppler, O.T. ; Pizzato, M.* ; Hornung, V.* ; Fackler, O.T.* ; Baldauf, H.-M.
The antiviral activity of rodent and lagomorph SERINC3 and SERINC5 is counteracted by known viral antagonists.
J. Gen. Virol. 100, 278-288 (2019)
Ayoubian, H.* ; Fröhlich, T.* ; Pogodski, D.* ; Flatley, A. ; Kremmer, E. ; Schepers, A. ; Feederle, R. ; Arnold, G.J.* ; Grässer, F.A.*
Antibodies against the mono-methylated arginine-glycine repeat (MMA-RG) of the Epstein-Barr virus nuclear antigen 2 (EBNA2) identify potential cellular proteins targeted in viral transformation.
J. Gen. Virol. 98, 2128-2142 (2017)
Meredith, L.W.* ; Hu, K.* ; Cheng, X. ; Howard, C.R.* ; Baumert, T.F.* ; Balfe, P.* ; van de Graaf, K.F.* ; Protzer, U. ; McKeating, J.A.
Lentiviral hepatitis B pseudotype entry requires NTCP and additional hepatocyte-specific factors.
J. Gen. Virol. 97, 121-127 (2016)
Yin, R.* ; Liu, X.* ; Bi, Y.* ; Xie, G.* ; Zhang, P.* ; Meng, X.* ; Ai, L.* ; Xu, R.* ; Sun, Y.* ; Stöger, T. ; Ding, Z.*
Expression of raf kinase inhibitor protein is down regulated in response to newcastle disease virus infection to promote viral replication.
J. Gen. Virol. 96, 2579-2586 (2015)
Hesse, J.* ; Ameres, S. ; Besold, K.* ; Krauter, S.* ; Moosmann, A. ; Plachter, B.*
Suppression of CD8+ T cell recognition in the immediate-early phase of human cytomegalovirus infection.
J. Gen. Virol. 94, 376-386 (2013)
Ohno, S. ; Steer, B. ; Sattler, C. ; Adler, H.
ORF23 of murine gammaherpesvirus 68 is non-essential for in vitro and in vivo infection.
J. Gen. Virol. 93, 1076-1080 (2012)
Haupt, S. ; Tisdale, M.* ; Vincendeau, M. ; Clements, M.A.* ; Gauthier, D.T.* ; Lance, R.* ; Semmes, O.J.* ; Turqueti-Neves, A. ; Nößner, E. ; Leib-Mösch, C. ; Greenwood, A.D.*
Human endogenous retrovirus transcription profiles of the kidney and kidney-derived cell lines.
J. Gen. Virol. 92, 2356-2366 (2011)
Ali, L.* ; Mansoor, A.* ; Ahmad, N. ; Siddiqi, S.* ; Mazhar, K.* ; Muazzam, A.G.* ; Qamar, R.* ; Khan, K.M.*
Patient HLA-DRB1* and -DQB1* allele and haplotype association with hepatitis C virus persistence and clearance.
J. Gen. Virol. 91, 1931-1938 (2010)
Backes, S.* ; Sperling, K.M.* ; Zwilling, J.* ; Gasteiger, G.* ; Ludwig, H.* ; Kremmer, E. ; Schwantes, A.* ; Staib, C.* ; Sutter, G.*
Viral host-range factor C7 or K1 is essential for modified vaccinia virus Ankara late gene expression in human and murine cells, irrespective of their capacity to inhibit protein kinase R-mediated phosphorylation of eukaryotic translation initiation factor 2α.
J. Gen. Virol. 91, 470-482 (2010)
Levin, A.* ; Hayouka, Z.* ; Friedler, A.* ; Brack-Werner, R. ; Volsky, D.J.* ; Loyter, A.*
A novel role for the viral Rev protein in promoting resistance to superinfection by human immunodeficiency virus type 1.
J. Gen. Virol. 91, 1503-1513 (2010)
Roupelieva, M.* ; Griffiths, S.J.* ; Kremmer, E. ; Meisterernst, M. ; Viejo-Borbolla, A.* ; Schulz, T.* ; Haas, J.*
Kaposi's sarcoma-associated herpesvirus Lana-1 is a major activator of the serum response element and mitogen-activated protein kinase pathways via interactions with the Mediator complex.
J. Gen. Virol. 91, 1138-1149 (2010)
Grabusic, K. ; Maier, S. ; Hartmann, A. ; Mantik, A. ; Hammerschmidt, W. ; Kempkes, B.
The CR4 region of EBNA2 convers viability of Epstein-Barr virus-transformed B cells by CBF1-independent signalling.
J. Gen. Virol. 87, 3169-3176 (2006)
Staib, C. ; Suezer, Y.* ; Kisling, S. ; Kalinke, U.* ; Sutter, G.*
Short-term, but not post-exposure, protection against lethal orthopoxvirus challenge after immunization with modified vaccinia virus Ankara.
J. Gen. Virol. 87, 2917-2921 (2006)
Schaadt, E. ; Baier, B. ; Mautner, J. ; Bornkamm, G.W. ; Adler, B.*
Epstein-Barr virus latent membrane protein 2A mimics B-cell receptor-dependent virus reactivation.
J. Gen. Virol. 86, 551-559 (2005)
Staib, C. ; Kisling, S. ; Erfle, V. ; Sutter, G.
Inactivation of the viral interleukin 1ß receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara.
J. Gen. Virol. 86, 1997-2006 (2005)
Koopman, G.* ; Mortier, D.* ; Hofmann, S.M.* ; Niphuis, H.* ; Fagrouch, Z.* ; Norley, S.* ; Sutter, G. ; Liljeström, P.* ; Heeney, J.L.*
Vaccine protection from CD4⁺ T-cell loss caused by simian immunodeficiency virus (SIV) mac251 is afforded by sequential immunization with three unrelated vaccine vectors encoding multiple SIV antigens.
J. Gen. Virol. 85, 2915-2924 (2004)
Mäkitalo, B.* ; Sutter, G. ; Erfle, V.
Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen.
J. Gen. Virol. 85, 2407-2419 (2004)
Nimmerjahn, F. ; Dudziak, D. ; Dirmeier, U. ; Hobom, G.* ; Riedel, A.* ; Schlee, M. ; Staudt, L.M.* ; Rosenwald, A.* ; Behrends, U.* ; Bornkamm, G.W. ; Mautner, J.*
Active NF-kB signalling is a prerequisite for influenza virus infection.
J. Gen. Virol. 85, 2347-2356 (2004)
Simas, J.P.* ; Marques, S.* ; Bridgeman, A.* ; Efstathiou, S.* ; Adler, H.
The M2 gene product of murine gammaherpesvirus 68 is required for efficient colonization of splenic follicles but is not necessary for expansion of latently infected germinal centre B cells.
J. Gen. Virol. 85, 2789-2797 (2004)
Meiser, A. ; Boulanger, D. ; Sutter, G. ; Krijnse Locker, J.*
Comparison of virus production in chicken embryo fibroblasts infected with the WR, IHD-J and MVA strains of vaccinia virus : IHD-J is most efficient in trans-Golgi network wrapping and extracellular eveloped virus release.
J. Gen. Virol. 84, 1383-1392 (2003)
Nilsson, C.* ; Sutter, G. ; Jallow-Walther, L.* ; Ten Haaft, P.* ; Akerblom, L.* ; Heeney, J.* ; Erfle, V. ; Böttiger, P.* ; Biberfeld, G.* ; Thorstensson, R.*
Immunization with recombinant modified vaccinia virus Ankara can modify mucosal simian immunodeficiency virus infection and delay disease progression in macaques.
J. Gen. Virol. 83, 807-818 (2002)
Wachinger, M. ; Kleinschmidt, A.* ; Winder, D.* ; von Pechmann, N. ; Ludvigsen, A. ; Neumann, M. ; Holle, R. ; Salmons, B.* ; Erfle, V. ; Brack-Werner, R.
Antimicrobial peptides melittin and cecropin inhibit replication of human immunodeficiency virus 1 by suppressing viral gene expression.
J. Gen. Virol. 79, 731-740 (1998)
Brielmeier, M. ; Mautner, J. ; Laux, G. ; Hammerschmidt, W.
The latent membrane protein 2 gene of Epstein-Barr virus is important for efficient B cell immortalization.
J. Gen. Virol. 77, 2807-2818 (1996)
Faff, O. ; Murray, A.B. ; Schmidt, J. ; Leib-Mösch, C. ; Erfle, V. ; Hehlmann, R.
Retrovirus-like Particles from the hum T47D Cell Line are Related to Mouse Mmary Tumour Virus and are of Human Endogenous Origin.
J. Gen. Virol. 73, 1087-1097 (1992)
Kirchner, E.A. ; Bornkamm, G.W. ; Polack, A.
Transcriptional Acitvity Across the Epstein-Barr Virus Genome in Raji Cells During Latency and After Induction of an Abortive Lytic Cycle.
J. Gen. Virol. 72, 2391-2398 (1991)
Laux, G. ; Economou, A. ; Farrell, P.J.
The Terminal Protein Gene 2 of Epstein-Barr Virus Is Transcribed from a Bidirectional Latent Promoter Region.
J. Gen. Virol. 70, 3079-3084 (1989)
Auling, G. ; Bernard, U. ; Huettermann, A. ; Mayer, F.C.
Characterization and comparison of the DNAs of the three closely related bacteriophages gd, ge and gf with the genome DNA of the hydrogen-oxidizing host strain Pseudomonas pseudoflava GA3.
J. Gen. Virol. 49, 51-59 (1980)